NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
SunTrust Downgrades NewLink Genetics (NLNK) to Neutral
May 11, 2016 6:49 AM EDTSunTrust Robinson Humphrey downgraded NewLink Genetics (NASDAQ: NLNK) from Buy to Neutral with a price target of $12.00 (from $59.00).
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $11.45 yesterday.
... MoreMizuho Securities Cuts Price Target on NewLink Genetics (NLNK) Following Failed IMPRESS Trial
May 10, 2016 1:22 PM EDTMizuho Securities maintained a Buy rating on NewLink Genetics (NASDAQ: NLNK), and cut the price target to $20.00 (from $52.00), following a failed IMPRESS Phase III trial.
Analyst Eric Criscuolo commented, "We reiterate our Buy rating but lower our PT from $52 to $20... More
Baird Highlighgs NewLink Genetics' (NLNK) IDO Program Amid Algenpantucel-L Failure
May 10, 2016 6:29 AM EDTBaird analyst Michael Ulz cut his price target on NewLink Genetics (NASDAQ: NLNK) to $23.00 (from $27.00) after Algenpantucel-L (cancer vaccine) failed to demonstrate a benefit in resected pancreatic cancer, with the control arm performing better than expected, as we they had cautioned. However, the firm... More
